

3050 Spruce Street Saint Louis, Missouri 63103 USA Telephone 800-325-5832 • (314) 771-5765 Fax (314) 286-7828 email: techserv@sial.com sigma-aldrich.com

ProductInformation

Sparsomycin from Streptomyces sparsogenes

Product Number S 1667 Storage Temperature 2-8 °C

Product Description

Molecular Formula: C₁₃H₁₉N₃O₅S₂

Molecular Weight: 361.4 CAS Number: 1404-64-4

Melting Point: 208-209 °C (with decomposition)¹ pK_a: 8.67 (in water), 9.05 (in 40% ethanol)¹ λ_{max} : 302 nm (water or 0.1 N aqueous H₂SO₄),

328 nm (0.1 N aqueous NaOH)

Synonyms: [R,[R*,S*-(E)]]-N-[1-(hydroxymethyl)-

2-[[(methylthio)methyl]sulfinyl]ethyl]-3-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-5-pyrimidinyl)-2-propenamide; (E)-(1S)-1,2,3,4-tetrahydro-N-[1-(hydroxymethyl)-2-[[(methylthio)methylsulfiniyl]ethyl]-6-methyl-2,4-dioxo-5-pyrimidine-acrylamide; NCS-59729;

U-19183

Sparsomycin is a metabolite from the fermentation of Streptomyces sparsogenes var. sparsogenes or Streptomyces cuspidosporus. It is an inhibitor of protein synthesis with antibiotic and antitumor activity. 1-3 The structural elucidation of sparsomycin has been described.4 Different syntheses of sparsomycin have been reported.5,6

The role of sparsomycin in tRNA translocation in the ribosome, in the absence of elongation factor G and guanosine triphosphate, has been investigated.⁷ The structure of sparsomycin bound to the large ribosomal subunit of Haloarcula marismortui at 3.0 Å resolution has been reported.8 Sparsomycin has been used in studies of mutant 23 S ribosomes to study the structural basis of catalysis and antibiotic resistance to oxazolidinones.9

A study of CD2F1 mice inoculated with L1210 cells has studied the antitumor activity of sparsomycin in conjunction with cis-platin. 10 The morphological reversion activity of sparsomycin on srctsNRK cells has been examined.6

Precautions and Disclaimer

For Laboratory Use Only. Not for drug, household or other uses.

Preparation Instructions

This product is soluble in water (2 mg/ml), yielding a clear, colorless solution.

References

- 1. The Merck Index, 12th ed., Entry# 8886.
- 2. Argoudelis, A. D., and Herr, R. R., Antimicrob. Ag. Chemother., 780 (1962).
- Goldberg, I. H., and Mitsugi, K., Sparsomycin inhibition of polypeptide synthesis promoted by synthetic and natural polynucleotides. Biochemistry, 6(2), 372-382 (1967).
- Wiley, P. F., and McKellar, F. A., Sparsomycin, structure and chemistry. J. Org. Chem., 41(10), 1858-1862 (1976).
- 5. Ottenheijm, H. C. J., Total synthesis of the antibiotic sparsomycin, a modified uracil amino acid monoxodithioacetal. J. Org. Chem., 46(16), 3273-3283 (1981).
- Nakajima, N., et al., Synthesis and morphological reversion activity on srctsNRK cells of pyrimidinylpropanamide antibiotics, sparsomycin, sparoxomycin A1, A2, and their analogues. Bioorg. Med. Chem. Lett., 8(23), 3331-3334 (1998).
- 7. Fredrick, K., and Noller, H. F., Catalysis of ribosomal translocation by sparsomycin. Science, **300(5622)**, 1159-1162 (2003).
- 8. Hansen, J. L., et al., Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J. Mol. Biol., 330(5), 1061-1075 (2003).

- Bobkova, E. V., et al., Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones. J. Biol. Chem., 278(11), 9802-9807 (2003).
- Zylicz, Z., et al., Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogues. Cancer Lett., 46(2), 153-157 (1989).

GCY/NSB 1/04